FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Narrative review on emergency colorectal cancer management in patients aged 80 years and older
Older patients with emergency colon cancer need geriatric care plans now
This narrative review synthesizes management strategies for emergency colorectal cancer in patients aged 80 years and older. It finds that b…
Most colon cancers in people over 80 cause emergencies that demand special geriatric care plans to save lives and preserve function
Review of glioma organoid models for mechanistic discovery and therapy development
Finally Lab-Grown Brain Models Could Speed Up Glioma Treatments
This narrative review summarizes glioma organoid model systems for studying tumor-neural interactions. It concludes these models provide a f…
• Tiny lab-grown brains mimic real tumor behavior better than old methods • Kids and adults fighting deadly brain cancers like glioblastoma …
Meta-analysis of PET/CT metabolic parameters for predicting NSCLC response after neoadjuvant therapy
New Scan Trick Spots Lung Cancer Treatment Success Weeks Earlier
This meta-analysis synthesized evidence on 18F-FDG PET/CT metabolic parameters for predicting major pathological response in non-small cell …
• Scans show if chemo shrinks tumors before surgery • Helps patients avoid unnecessary risky operations • Hospitals need more testing before…
FDA Approves Ziextenzo (pegfilgrastim-bmez) for Febrile Neutropenia and Acute Radiation Syndrome
FDA approves new biosimilar drug Ziextenzo to prevent infections in cancer patients.
The FDA approved Ziextenzo (pegfilgrastim-bmez) to decrease febrile neutropenia in patients with non-myeloid malignancies receiving myelosup…
The FDA approved Ziextenzo, a biosimilar to Neulasta, to prevent infections in cancer patients receiving chemotherapy and to treat radiation…
FDA Approves Abiraterone Acetate (Yonsa) for Metastatic Castration-Resistant Prostate Cancer
FDA approves new prostate cancer drug Yonsa to slow tumor growth.
The FDA approved abiraterone acetate (Yonsa) in combination with methylprednisolone for metastatic castration-resistant prostate cancer. The…
The FDA approved Yonsa (abiraterone acetate) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy…
FDA Approves Tecentriq Hybreza (atezolizumab/hyaluronidase) for Multiple Cancers
FDA approves new shot form of cancer drug Tecentriq Hybreza
The FDA approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab with hyaluronidase, for multiple indications including NSCLC,…
The FDA approved Tecentriq Hybreza, a new injectable form of the cancer drug atezolizumab, for several types of cancer including lung cancer…
FDA Approves Tecentriq (atezolizumab) for Alveolar Soft Part Sarcoma
FDA approves first drug for rare soft tissue sarcoma in children and adults.
The FDA approved Tecentriq (atezolizumab) for adult and pediatric patients 2 years and older with unresectable or metastatic alveolar soft p…
The FDA approved Tecentriq for alveolar soft part sarcoma (ASPS), a rare cancer that often spreads. This is the first treatment specifically…
Postoperative exercise interventions shorten intestinal recovery time in colorectal cancer surgery
Exercise plans may help colorectal surgery recovery
This systematic review and meta-analysis of 13,124 patients with colorectal cancer found that postoperative comprehensive interventions sign…
A review of studies found that exercise before or after colorectal surgery can help patients recover faster, but it may not prevent a common…
Prolonged time-to-surgery after chemoradiotherapy improves preoperative quality of life in esophageal cancer
Waiting Longer for Esophageal Cancer Surgery Backfires Despite Feeling Better
This randomized controlled trial in patients with locally advanced resectable esophageal cancer compared prolonged (10-12 weeks) versus stan…
• Longer wait worsens cancer outcomes despite better pre-op quality of life • Helps patients facing surgery after chemoradiotherapy • Standa…
Systematic review and meta-analysis suggests Lanqin Oral Liquid plus Western medicine improves pharyngitis outcomes versus Western medicine alone
Combining Lanqin Oral Liquid with standard Western medicine treatment helps patients with sore throat heal faster and feel better
This systematic review and meta-analysis evaluated Lanqin Oral Liquid combined with Western medicine for pharyngitis compared to Western med…
A review of twelve studies found that adding Lanqin Oral Liquid to standard Western medicine helps patients with pharyngitis heal faster. Th…
Case report and literature review highlights skin lesions as early AITL signs before lymphadenopathy
When a Skin Rash Signals a Hidden Blood Cancer
This case report and literature review examines cutaneous manifestations in a 63-year-old male with Angioimmunoblastic T-cell lymphoma treat…
A rare lymphoma can hide behind common-looking skin rashes and ulcers, causing dangerous delays in diagnosis that may last months.